Non-erythropoiesis-stimulating agent, non-iron therapies for the management of anaemia: protocol for a scoping review

IntroductionPreoperative anaemia is associated with poor postoperative outcomes and is the strongest predictor of allogenic blood transfusion, which contributes further to patient morbidity. Emphasis has been placed on correcting anaemia prior to surgery to mitigate these outcomes. Conflicting evide...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open 2022-04, Vol.12 (4), p.e059059-e059059
Main Authors: Devlin, Paula, Davies, Amelia, Dugan, Cory, Richards, Toby, Miles, Lachlan F
Format: Article
Language:English
Subjects:
Abdominal surgery
Adult anaesthesia
Anaemia
Anaesthesia
Anemia
Anemia - drug therapy
Antibodies
Blood bank & transfusion medicine
Blood Transfusion
Blood transfusions
Clinical outcomes
Hematology
Hemoglobin
Humans
Intervention
Iron
Kidney diseases
Meta-analysis
Outcome Assessment, Health Care
Patient-centered care
Patients
Peer Review
Postoperative period
Proteins
Renal Insufficiency, Chronic
Research Design
Review Literature as Topic
SURGERY
Systematic review
Systematic Reviews as Topic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IntroductionPreoperative anaemia is associated with poor postoperative outcomes and is the strongest predictor of allogenic blood transfusion, which contributes further to patient morbidity. Emphasis has been placed on correcting anaemia prior to surgery to mitigate these outcomes. Conflicting evidence exists regarding the benefit of currently recommended interventions. With greater understanding of iron haemostasis and erythropoiesis, novel therapies have been identified. These are at varying stages of development with some demonstrating promising results in patients with chronic kidney disease. It is not known how these agents have been studied outside this population, particularly in the perioperative context. To address this, we will conduct a scoping review of the published literature to chart the evidence.Methods and analysisThe scoping review will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews framework. The electronic database search will include Scopus, MEDLINE (Ovid) and Excerpta Medica database (Ovid), with no language restrictions, and will include all publications since 1 January 2010. This review will have three objectives: (1) to describe the mechanisms of action for novel agents, (2) to describe the level of evidence and stage of development of novel agents in a perioperative setting, and (3) to determine the potential agents suitable for prospective controlled trials in a preoperative or postoperative patient cohort and aiming to improve patient-centred outcomes. The review process will involve two reviewers with a third reviewer resolving disagreements. Data will be extracted and organised with subsequent analysis.Ethics and disseminationThis scoping review does not require research ethics approval. The results will be published in a peer-reviewed journal and inform the development of future prospective trials based on established evidence from potential therapeutic agents.Trial registration numberThis protocol has been registered prospectively on the Open Science Framework registry (DOI:10.17605/OSF.IO/SM3UH, https://osf.io/sm3uh/?view_only=39876ccf7a4348dfbd566535b957a7db).Cite Now
ISSN:2044-6055
2044-6055
DOI:10.1136/bmjopen-2021-059059